| Name | Clofibric acid |
| Description | Clofibric acid (Chlorofibrinic acid) is an antilipemic agent that is the biologically active metabolite of CLOFIBRATE. |
| In vitro | Clofibric acid enhances the expression of carbonyl reductase in vivo, reduces PGE2 levels, and diminishes the quantity of vascular endothelial growth factor (VEGF) in OVCAR-3 tumors and DISS-origin ascites. In solid OVCAR-3 tumors, it decreases microvascular density and induces apoptosis. Compared to the control, a 9,000 ppm Clofibric acid diet significantly reduces the growth of OVCAR-3 tumor xenografts s.c. by 46% and notably prolongs the survival of mice with DISS-origin malignant ascites. |
| In vivo | Clofibric acid enhances the expression of the CYP4A6 gene in RK13 cells transfected with PPAR-Gamma. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.32 mM), Sonication is recommended.
Ethanol : 40 mg/mL (186.35 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 250 mg/mL (1164.69 mM), Sonication is recommended.
|
| Keywords | PPAR | Peroxisome proliferator-activated receptors | Inhibitor | inhibit | DrugMetabolite | Drug Metabolite | Clofibric acid |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Daidzein | Metronidazole | Doxycycline | Dimethyl sulfoxide | Sodium diacetate | BES |
| Related Compound Libraries | Nuclear Receptor Compound Library | Pesticide Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | High Solubility Fragment Library | Anti-Cancer Drug Library | Anti-Hypertension Compound Library |
United States
